BRPI0908268A2 - compostos do inibidor de raf e seus métodos de uso - Google Patents

compostos do inibidor de raf e seus métodos de uso

Info

Publication number
BRPI0908268A2
BRPI0908268A2 BRPI0908268A BRPI0908268A BRPI0908268A2 BR PI0908268 A2 BRPI0908268 A2 BR PI0908268A2 BR PI0908268 A BRPI0908268 A BR PI0908268A BR PI0908268 A BRPI0908268 A BR PI0908268A BR PI0908268 A2 BRPI0908268 A2 BR PI0908268A2
Authority
BR
Brazil
Prior art keywords
methods
inhibitor compounds
raf inhibitor
raf
compounds
Prior art date
Application number
BRPI0908268A
Other languages
English (en)
Inventor
J Buckmelter Alexandre
Feng Bainian
Newhouse Brad
Moreno David
R Laird Ellen
Tian Hongqi
Gunzner Janet
De Meese Jason
Seo Jeongbeob
Rudolph Joachim
Grina Jonas
D Hansen Joshua
A Ahrendt Kateri
Malesky Kimberly
Ren Li
Lunghofer Paul
Mathieu Simon
Mark Wenglowsky Steven
B Young Wendy
Wen Zhaoyang
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of BRPI0908268A2 publication Critical patent/BRPI0908268A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0908268A 2008-02-29 2009-02-27 compostos do inibidor de raf e seus métodos de uso BRPI0908268A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3281308P 2008-02-29 2008-02-29
PCT/US2009/035381 WO2009111279A1 (en) 2008-02-29 2009-02-27 Pyrazole [3, 4-b] pyridine raf inhibitors

Publications (1)

Publication Number Publication Date
BRPI0908268A2 true BRPI0908268A2 (pt) 2018-10-30

Family

ID=40677552

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908268A BRPI0908268A2 (pt) 2008-02-29 2009-02-27 compostos do inibidor de raf e seus métodos de uso

Country Status (19)

Country Link
US (1) US8394795B2 (pt)
EP (1) EP2265610B1 (pt)
JP (1) JP2011513331A (pt)
KR (1) KR20100117686A (pt)
CN (1) CN102149712A (pt)
AR (1) AR072657A1 (pt)
AU (1) AU2009222144A1 (pt)
BR (1) BRPI0908268A2 (pt)
CA (1) CA2716952A1 (pt)
CL (1) CL2009000448A1 (pt)
CR (1) CR11690A (pt)
EC (1) ECSP10010507A (pt)
ES (1) ES2400202T3 (pt)
IL (1) IL207845A0 (pt)
MA (1) MA32272B1 (pt)
MX (1) MX2010009411A (pt)
PE (1) PE20091623A1 (pt)
TW (1) TW200940539A (pt)
WO (1) WO2009111279A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2009089462A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
WO2009111277A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
EP2265608A2 (en) * 2008-02-29 2010-12-29 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
TWI404719B (zh) 2009-04-03 2013-08-11 Hoffmann La Roche 組合物及其用途
PT2462119E (pt) * 2009-08-03 2014-07-25 Acraf Processo para a preparação de 1-benzil-3-hidroximetil-1 hindazole e derivados do mesmo e intermédios de magnésio requeridos
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013503187A (ja) * 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
CA2772316A1 (en) * 2009-08-28 2011-03-03 Array Biopharma Inc. 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase
US20110112127A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CA2824028A1 (en) 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Novel ureas for the treatment and prevention of cancer
EP2672967B1 (en) 2011-02-07 2018-10-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
EP2758055A1 (en) 2011-09-19 2014-07-30 F.Hoffmann-La Roche Ag Combination treatments comprising c-met antagonists and b-raf antagonists
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
WO2013127268A1 (en) * 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
CA2872014A1 (en) 2012-05-08 2013-11-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20170044759A (ko) 2012-08-17 2017-04-25 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
EP3590922A1 (en) * 2013-03-15 2020-01-08 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014194127A1 (en) * 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
AP2016009025A0 (en) * 2013-07-08 2016-02-29 Bayer Pharma AG Substituted pyrazolo-pyridinamines
CA2922230A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
MX2017000546A (es) 2014-07-15 2017-03-08 Genentech Inc Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
CN107074828B (zh) * 2014-09-12 2020-05-19 诺华股份有限公司 用作raf激酶抑制剂的化合物和组合物
MX2018006152A (es) 2015-11-19 2018-09-17 Genentech Inc Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
CA3079837A1 (en) * 2017-11-01 2019-05-09 The Board Of Trustees Of The Leland Stanford Junior University Analyte detection method
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CN111171019A (zh) * 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
CN110627691B (zh) * 2019-08-20 2022-03-25 中船(邯郸)派瑞特种气体股份有限公司 一种制备n-苯基-双(全氟烷基磺酰)亚胺的方法
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6121M (pt) * 1966-01-12 1968-06-17
NZ186175A (en) * 1977-01-27 1980-03-05 Shionogi & Co Meta-sulphonamidobenzamide derivatives
US5800711A (en) * 1996-10-18 1998-09-01 Mdv Technologies, Inc. Process for the fractionation of polyoxyalkylene block copolymers
AU747705C (en) 1997-12-13 2004-09-23 Bristol-Myers Squibb Company Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors
TR200002618T2 (tr) 1997-12-22 2001-04-20 Bayer Corporation Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi
BR9814375A (pt) 1997-12-22 2002-05-21 Bayer Ag Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
CN1117081C (zh) 1997-12-22 2003-08-06 拜尔有限公司 用芳基取代或杂芳基取代的杂环脲抑制raf激酶
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru) * 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030207914A1 (en) * 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US20020192289A1 (en) * 2001-06-18 2002-12-19 Ji Zheng Polymer gel for cancer treatment
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
AU2003245700A1 (en) 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
WO2004084703A2 (en) * 2003-03-24 2004-10-07 Biosphere Medical, Inc. Temporary embolization using inverse thermosensitive polymers
CN1805748B (zh) * 2003-06-13 2010-05-26 诺瓦提斯公司 作为raf激酶抑制剂的2-氨基嘧啶衍生物
ATE538787T1 (de) * 2003-07-11 2012-01-15 Merck Patent Gmbh Benzimidazol-derivative als raf-kinase-hemmer
CA2531856C (en) * 2003-07-11 2013-07-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Benzimidazole carboxamides as raf kinase inhibitors
BRPI0412684A (pt) * 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
CA2542105C (en) * 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
CN1882345A (zh) * 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
WO2005037273A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
AU2004308299B2 (en) 2003-12-19 2011-11-24 Plexxikon, Inc. Compounds and methods for development of Ret modulators
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
AU2005278959A1 (en) * 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as B-Raf inhibitors
CN101010303A (zh) * 2004-09-01 2007-08-01 阿斯利康(瑞典)有限公司 喹唑啉酮衍生物和它们作为b－raf抑制剂的用途
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2005297531B2 (en) 2004-10-13 2011-06-23 Merck Patent Gmbh Phenylurea derivatives used as inhibitors of tyrosinkinase for treating tumors
WO2006040039A1 (de) 2004-10-13 2006-04-20 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n, n ´ -diphenylharnstoffs
CA2583096A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
TW200634003A (en) 2004-12-22 2006-10-01 Astrazeneca Ab Chemical compounds
JP2008525355A (ja) 2004-12-23 2008-07-17 エフ．ホフマン−ラ ロシュ アーゲー ベンズアミド誘導体、これらの製造及び医薬剤としての使用。
EP1835934A4 (en) * 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
EP1924573A1 (en) * 2005-01-25 2008-05-28 AstraZeneca AB B-raf inhibitors
RU2368602C2 (ru) * 2005-01-26 2009-09-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EP1871773A1 (en) * 2005-03-17 2008-01-02 Novartis AG N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
CN101175753B (zh) * 2005-05-13 2011-03-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
MX2007014377A (es) 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
WO2006125101A2 (en) * 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
ATE518860T1 (de) 2005-06-22 2011-08-15 Plexxikon Inc Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
WO2007017143A1 (en) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
AU2006279992A1 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20080052630A (ko) * 2005-09-01 2008-06-11 어레이 바이오파마 인크. Ｒａｆ 억제제 화합물 및 그의 사용 방법
KR100968099B1 (ko) * 2005-09-15 2010-07-06 에프. 호프만-라 로슈 아게 4-아미노-티에노[3,2-ｃ]피리딘-7-카르복실산 유도체
JP2009514899A (ja) * 2005-11-04 2009-04-09 スミスクライン ビーチャム コーポレーション チエノピリジンＢ−Ｒａｆキナーゼ阻害剤
CA2632512A1 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
RU2442778C9 (ru) 2005-12-13 2012-08-10 Шеринг Корпорейшн Новые соединения, действующие как ингибиторы erk
KR20080079673A (ko) * 2005-12-22 2008-09-01 아스트라제네카 아베 퀴나졸린 유도체, 이의 제조 방법 및 항암제로서의 이의용도
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
WO2007076460A2 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Substituted thiazole ureas useful as inhibitors of protein kinases
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
CN101415688A (zh) * 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有b-raf抑制活性的喹唑啉酮衍生物
JP2009532449A (ja) * 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ 抗癌活性のある置換キナゾリン
EP2010504A1 (en) * 2006-04-18 2009-01-07 AstraZeneca AB Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
US20070224169A1 (en) * 2006-07-18 2007-09-27 Sliwa John W Jr Selectively switched gels for surgery, therapy and maintenance
AU2007294149A1 (en) * 2006-09-06 2008-03-13 F. Hoffmann-La Roche Ag Heteroaryl derivatives as protein kinase inhibitors
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN103739595A (zh) * 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2008044688A1 (fr) 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Dérivé de l'urée
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008073938A2 (en) * 2006-12-11 2008-06-19 Pluromed, Inc. Perfusive organ hemostasis
US7872018B2 (en) * 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008112695A2 (en) 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2008124393A1 (en) 2007-04-04 2008-10-16 Irm Llc Benzothiazole derivatives and their use as protein kinase inhibitors
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
AU2008266290A1 (en) * 2007-06-15 2008-12-24 Irm Llc Protein kinase inhibitors and methods for using thereof
WO2008157575A1 (en) * 2007-06-21 2008-12-24 Irm Llc Protein kinase inhibitors and methods for using thereof
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
JP5270553B2 (ja) * 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028629A1 (ja) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
WO2009111277A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
EP2265608A2 (en) * 2008-02-29 2010-12-29 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
SG10201608813PA (en) * 2008-03-17 2016-12-29 Ambit Biosciences Corp Quinazoline derivatives as raf kinase modulators and methods of use thereof
GB0807609D0 (en) * 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8158636B2 (en) * 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009152087A1 (en) * 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
AU2009257635A1 (en) * 2008-06-10 2009-12-17 Plexxikon, Inc. 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물

Also Published As

Publication number Publication date
TW200940539A (en) 2009-10-01
MX2010009411A (es) 2010-11-30
US8394795B2 (en) 2013-03-12
MA32272B1 (fr) 2011-05-02
AR072657A1 (es) 2010-09-15
CN102149712A (zh) 2011-08-10
ES2400202T3 (es) 2013-04-08
KR20100117686A (ko) 2010-11-03
EP2265610A1 (en) 2010-12-29
JP2011513331A (ja) 2011-04-28
WO2009111279A1 (en) 2009-09-11
CA2716952A1 (en) 2009-09-11
PE20091623A1 (es) 2009-11-19
EP2265610B1 (en) 2012-12-12
IL207845A0 (en) 2010-12-30
AU2009222144A1 (en) 2009-09-11
US20110092479A1 (en) 2011-04-21
CR11690A (es) 2010-11-02
CL2009000448A1 (es) 2009-11-27
ECSP10010507A (es) 2010-10-30

Similar Documents

Publication Publication Date Title
BRPI0908268A2 (pt) compostos do inibidor de raf e seus métodos de uso
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
CY2019010I2 (el) Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
SMT201600278B (it) Inibitori della benzossazolo chinasi e metodi d'uso
BRPI0910346A2 (pt) compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso
BRPI1011384A2 (pt) pro-proteinas e seus metodos de uso
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
IL207843A0 (en) Raf inhibitor compounds and methods of use thereof
CR20130360A (es) Compuesto heterocíclico y su uso
BRPI0916269A2 (pt) dispositivo de modificação de tecido e seu método de uso
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0921862A2 (pt) inibidores de raf e seus usos
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0817881A2 (pt) Compostos orgânicos e seus usos
BRPI0918693A2 (pt) dispositivos para amostragem e métodos para concentração de microorganismos
BRPI1011129A2 (pt) métodos e compostos inibidores de janus cinase
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI0915717A2 (pt) ferramenta de avaliação de cascalho e métodos de uso
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0922344A2 (pt) inibidores de tfpi e métodos de uso
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BRPI0911332A2 (pt) composições e uso de inibidores de epas1
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BRPI1007494A2 (pt) composto e uso do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.